Clinical Trial

Administration of Intranasal Midazolam for Anxiety in Palliative Care

Study acronym: AIM Care
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study (three study arms) is to describe effects and safety of different doses of intranasal midazolam to treat acute anxiety in palliative care patients, while providing pharmacokinetic and pharmacodynamic data.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-03-18; most recent amendment 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06330584
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Anxiety, Acute Anxiety, Palliative Care
Enrollment 36 participants
Start Date 2024-12-20
Primary Completion 2025-09 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-10